TABLE 1.
Association between circPCBP2 expression levels and clinicopathological features of DLBCL patients
| Clinical parameters | Cases (n) | circPCBP2 expression | p‐value (*p < 0.05) | |
|---|---|---|---|---|
| High (n) | Low (n) | |||
| Gender | ||||
| Male | 37 | 20 | 17 | 0.426 |
| Female | 23 | 10 | 13 | |
| Age | ||||
| <60 | 31 | 17 | 14 | 0.438 |
| ≥60 | 29 | 13 | 16 | |
| Stages | ||||
| I–II | 27 | 9 | 18 | 0.019* |
| III–IV | 33 | 21 | 12 | |
| LDH | ||||
| Normal | 24 | 8 | 16 | 0.035* |
| Elevated | 36 | 22 | 14 | |
| IPI score | ||||
| Low (0–2) | 24 | 14 | 10 | 0.292 |
| High (3–5) | 36 | 16 | 20 | |
| Hans classification | ||||
| GCB | 20 | 9 | 11 | 0.584 |
| Non‐GCB | 40 | 21 | 19 | |
| EBER | ||||
| Negative | 43 | 23 | 20 | 0.738 |
| Positive | 17 | 7 | 10 | |
Abbreviations: DLBCL, diffuse large B‐cell lymphoma; EBER, EBV‐encoded RNA; GCB, germinal center B‐like; IPI, International Prognostic Index; LDH, lactate dehydrogenase.
*represents the p‐value < 0.05.